Risk of Major Bleeding with Ibrutinib
Ibrutinib is a highly effective therapy in NHL and CLL. However, ibrutinib is associated with an increased risk of bleeding, although major bleeding has been infrequent in clinical trials. In this retrospective analysis, major bleeding occurred in 19% of patients on ibrutinib and was associated with baseline anemia, elevated INR and concurrent antiplatelet and anticoagulant use. Risk versus benefit analysis of these factors is essential in treatment with ibrutinib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Joseph Mock, Paul R. Kunk, Surabhi Palkimas, Jeremy M. Sen, Michael Devitt, Bethany Horton, Craig A. Portell, Michael E. Williams, Hillary Maitland Tags: Original Study Source Type: research